Company / PP&E (Net)
KYNTRA BIO, INC. PP&E (Net) History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$13.1M
FY2023
5-year range
$13.1M / $33.6M
FY2019-FY2023
Trend
-36.3%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $34M to $13M over the past 2 years.
Based on SEC 10-K filings.
$13M in FY2023 with a 5-year CAGR of -36.5%.
Declined from $34M to $13M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -26.9%
- 5-Year CAGR
- -36.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -36.5%, indicating a declining trend.
- In FY2023, pp&e (net) decreased 36.3% year-over-year.
- Peak pp&e (net) was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.33 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $13.1M | -36.3% |
| FY2022 | $20.6M | -38.8% |
| FY2021 | $33.6M | +0.0% |
| FY2020 | $33.6M | -21.3% |
| FY2019 | $42.7M | -66.4% |
| FY2018 | $127.2M | -1.8% |
| FY2017 | $129.5M | +4.7% |
| FY2016 | $123.7M | -4.2% |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026